Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) – Equities researchers at B. Riley issued their Q2 2019 EPS estimates for Arrowhead Pharmaceuticals in a report issued on Monday, February 11th. B. Riley analyst M. Kumar forecasts that the biotechnology company will earn $0.10 per share for the quarter. B. Riley also issued estimates for Arrowhead Pharmaceuticals’ Q3 2019 earnings at $0.15 EPS, Q4 2019 earnings at $0.48 EPS, FY2019 earnings at $1.10 EPS, FY2020 earnings at ($0.24) EPS and FY2021 earnings at ($1.26) EPS.
Arrowhead Pharmaceuticals (NASDAQ:ARWR) last posted its earnings results on Thursday, February 7th. The biotechnology company reported $0.13 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.76 by ($0.63). The business had revenue of $34.66 million for the quarter, compared to analyst estimates of $90.88 million. Arrowhead Pharmaceuticals had a negative net margin of 61.78% and a negative return on equity of 24.23%.
ARWR has been the subject of several other research reports. Cantor Fitzgerald set a $24.00 price objective on shares of Arrowhead Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, December 11th. William Blair restated an “outperform” rating on shares of Arrowhead Pharmaceuticals in a report on Wednesday, October 17th. Finally, Chardan Capital reiterated a “buy” rating and set a $24.50 target price on shares of Arrowhead Pharmaceuticals in a report on Monday. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $21.36.
ARWR stock opened at $17.28 on Wednesday. The stock has a market cap of $1.45 billion, a PE ratio of -26.58 and a beta of 2.23. Arrowhead Pharmaceuticals has a 52 week low of $5.01 and a 52 week high of $22.39.
Hedge funds have recently bought and sold shares of the business. Lindbrook Capital LLC acquired a new position in Arrowhead Pharmaceuticals in the fourth quarter worth approximately $52,000. Advisor Group Inc. lifted its holdings in shares of Arrowhead Pharmaceuticals by 73.4% during the fourth quarter. Advisor Group Inc. now owns 8,670 shares of the biotechnology company’s stock valued at $109,000 after acquiring an additional 3,670 shares during the period. Stratos Wealth Partners LTD. acquired a new stake in shares of Arrowhead Pharmaceuticals in the third quarter valued at $123,000. Wealth Architects LLC acquired a new stake in shares of Arrowhead Pharmaceuticals in the fourth quarter valued at $124,000. Finally, Beaumont Financial Partners LLC acquired a new stake in Arrowhead Pharmaceuticals in the fourth quarter worth about $124,000. 59.52% of the stock is owned by institutional investors.
In other news, COO Bruce D. Given sold 46,167 shares of the company’s stock in a transaction dated Friday, February 8th. The shares were sold at an average price of $15.34, for a total transaction of $708,201.78. Following the completion of the transaction, the chief operating officer now owns 859,523 shares in the company, valued at $13,185,082.82. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Bruce D. Given sold 242,834 shares of the company’s stock in a transaction dated Tuesday, February 12th. The stock was sold at an average price of $16.04, for a total transaction of $3,895,057.36. Following the transaction, the chief operating officer now owns 859,523 shares of the company’s stock, valued at approximately $13,786,748.92. The disclosure for this sale can be found here. Over the last three months, insiders have sold 972,375 shares of company stock worth $14,143,250. Corporate insiders own 4.80% of the company’s stock.
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company offers ARO-AAT, a RNA interference (RNAi) therapeutic candidate for the treatment of liver disease related to alpha-1 antitrypsin deficiency; ARO-APOC3 to treat hypertriglyceridemia; ARO-ANG3 to reduce production of angiopoietin-like protein 3; ARO-ENaC to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; and ARO-HIF2 for the treatment of clear cell renal cell carcinoma.
Read More: What are the Benefits of Index Funds?
Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.